Idenix Pharmaceuticals, Inc. (IDIX) Reports Q3 Loss of 12c

November 2, 2011 5:01 PM EDT
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.64 million versus the consensus estimate of $2.56 million.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings